2248703-42-4

SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a Ki of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate (S1P) and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models[1][2].

SACLAC is an irreversible inhibitor of acid ceramidase (Ki = 97.1 nM) and a derivative of the acid ceramidase inhibitor SABRAC .1 It decreases levels of sphingosine-1-phosphate (S1P) and increases total ceramide levels in OCI-AML-2 acute myeloid leukemia (AML) cells when used at a concentration of 2.5 μM.2 SACLAC (10 and 20 μM) induces apoptosis in primary AML cells. It reduces leukemic burden in MV4-11 and U937 AML mouse xenograft models when administered at a dose of 5 mg/kg.

-20°C

1.Ordó?ez, Y.F., Abad, J.L., Aseeri, M., et al.Activity-based imaging of acid ceramidase in living cellsJ. Am. Chem. Soc.141(19)7736-7742(2019) 2.Pearson, J.M., Tan, S.-F., Sharma, A., et al.Ceramide analogue SACLAC modulates sphingolipid levels and MCL-1 splicing to induce apoptosis in acute myeloid leukemiaMol. Cancer Res.18(3)352-363(2020)